- Home
- KALV vs VIR Comparison
KALV vs VIR Comparison
Compare KALV & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALV
- VIR
- Stock Information
- Founded
- KALV N/A
- VIR 2016
- Country
- KALV United States
- VIR United States
- Employees
- KALV N/A
- VIR N/A
- Industry
- KALV Biotechnology: Pharmaceutical Preparations
- VIR Biotechnology: Pharmaceutical Preparations
- Sector
- KALV Health Care
- VIR Health Care
- Exchange
- KALV Nasdaq
- VIR Nasdaq
- Market Cap
- KALV 642.3M
- VIR 706.4M
- IPO Year
- KALV N/A
- VIR 2019
- Fundamental
- Price
- KALV $14.31
- VIR $5.65
- Analyst Decision
- KALV Strong Buy
- VIR Strong Buy
- Analyst Count
- KALV 9
- VIR 8
- Target Price
- KALV $26.29
- VIR $30.25
- AVG Volume (30 Days)
- KALV 2.0M
- VIR 1.2M
- Earning Date
- KALV 07-10-2025
- VIR 07-31-2025
- Dividend Yield
- KALV N/A
- VIR N/A
- EPS Growth
- KALV N/A
- VIR N/A
- EPS
- KALV N/A
- VIR N/A
- Revenue
- KALV N/A
- VIR $20,861,000.00
- Revenue This Year
- KALV N/A
- VIR N/A
- Revenue Next Year
- KALV $347.19
- VIR $0.62
- P/E Ratio
- KALV N/A
- VIR N/A
- Revenue Growth
- KALV N/A
- VIR N/A
- 52 Week Low
- KALV $7.30
- VIR $4.32
- 52 Week High
- KALV $16.32
- VIR $14.45
- Technical
- Relative Strength Index (RSI)
- KALV 58.58
- VIR 57.21
- Support Level
- KALV $11.10
- VIR $5.20
- Resistance Level
- KALV $16.32
- VIR $6.23
- Average True Range (ATR)
- KALV 1.10
- VIR 0.30
- MACD
- KALV 0.36
- VIR 0.07
- Stochastic Oscillator
- KALV 68.95
- VIR 56.06
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.